Jade Biosciences, Inc. is a clinical-stage biotechnology company dedicated to developing novel, best-in-class therapies for autoimmune and inflammatory diseases. The company's pipeline is built on discovery-stage assets licensed from Paragon Therapeutics, an antibody discovery engine. Jade's lead clinical candidate, JADE101, is a monoclonal antibody designed to inhibit the cytokine APRIL (A Proliferation-Inducing Ligand). It is currently in clinical development for the treatment of immunoglobulin A nephropathy (IgAN), a chronic kidney disease that can progressively impair kidney function. By targeting the APRIL pathway, JADE101 aims to reduce harmful IgA antibodies and preserve long-term kidney function. The company's broader pipeline includes JADE201, an anti-BAFF-R (B-cell activating factor receptor) monoclonal antibody being developed for rheumatoid arthritis and other autoimmune indications, as well as JADE301, an undisclosed preclinical antibody program. As a pre-revenue, clinical-stage company, Jade Biosciences does not currently generate product sales and relies on equity financing to fund its research and development activities. The company operates primarily in the United States and became a publicly traded entity following a reverse merger with Aerovate Therapeutics in April 2025.
